Citations

Clear

1792 citation(s) found for "Stephanie".

Bridging the gap: Multi‐omics profiling of brain tissue in Alzheimer's disease and older controls in multi‐ethnic populations
Reddy, Joseph S. , Heath, Laura , Linden, Abby Vander , Allen, Mariet , Lopes, Kátia de Paiva , Wang, Erming , Poehlman, William L. , Quicksall, Zachary , Runnels, Alexi , Duong, Duc M. , Yin, Luming, Xu, Kaiming , Modeste, Erica , Dammer, Eric B. , Ping, Lingyan , Oatman, Stephanie R., Scanlan, Jo, Ho, Charlotte C.G. , Carrasquillo, Minerva M. , Atık, Merve, Yepez, Geovanna, Mitchell, Adriana O., Nguyen, Thuy , Chen, Xianfeng , Reddy, Hasini, Xiao, Harrison, Seshadri, Sudha , Mayeux, Richard , Beach, Thomas G. , Haroutunian, V., Fox, Edward J., Gearing, Marla , Wingo, Aliza P. , Wingo, Thomas S. , Jager, Philip L. De , Zhang, Bin , Bennett, David A. , Seyfried, Nicholas T. , Greenwood, Anna K. , Ertekin‐Taner, Nilüfer , Bennett, David A. , Ho, Charlotte, Greenwood, Anna K , Seshadri, Sudha , Dammer, Eric B , Wingo, Thomas S , Seifar, Fatemeh , Ma, Yiyi , Wang, Yanling , Shantaraman, Anantharaman , Carrasquillo, Minerva M. , Márquez, David X. , Prokop, Stefan , Lee, Edward B. , Serrano, Geidy E. , Teich, Andrew F. , Lah, James J. , Levey, Allan I. , Dickson, Dennis W. , Barnes, Lisa L.

Mayo Clinic

Alzheimer's & Dementia | August 31, 2024 | Volume: 20 | Issue: 10 | Pages: 7174-7192

10.1002/alz.14208 | PMID 39215503 Get It

Abstract INTRODUCTION Multi‐omics studies in Alzheimer's disease (AD) revealed many potential disease pathways and therapeutic targets. Despite their promise of precision medicine, these studies lacked Black Americans (BA) and Latin Americans (LA), who are disproportionately affected by AD. METHODS To bridge this gap, Accelerating Medicines Partnership in Alzheimer's Disease (AMP‐AD) expanded brain multi‐omics profiling to multi‐ethnic donors. RESULTS We generated multi‐omics data and curated and harmonized phenotypic data from BA ( n = 306), LA ( n = 326), or BA and LA ( n = 4) brain donors plus non‐Hispanic White ( n = 252) and other ( n = 20) ethnic groups, to establish a foundational dataset enriched for BA and LA participants. This study describes the data available to the research community, including transcriptome from three brain regions, whole genome sequence, and proteome measures. DISCUSSION The inclusion of traditionally underrepresented groups in multi‐omics studies is essential to discovering the full spectrum of precision medicine targets that will be pertinent to all populations affected with AD. Highlights Accelerating Medicines Partnership in Alzheimer's Disease Diversity Initiative led brain tissue profiling in multi‐ethnic populations. Brain multi‐omics data is generated from Black American, Latin American, and non‐Hispanic White donors. RNA, whole genome sequencing and tandem mass tag proteomicsis completed and shared. Multiple brain regions including caudate, temporal and dorsolateral prefrontal cortex were profiled.
Let it glow: Intraoperative visualization of pulmonary metastases using pafolacianine, a next‐generation fluorescent agent, for young adults undergoing pulmonary metastasectomy
Lehane, Alison , Polites, Stephanie F. , Dodd, Ashley , Lautz, Timothy B. , Lautz, Timothy , Goldstein, Seth D.

Mayo Clinic

Pediatric Blood & Cancer | August 28, 2024 | Volume: 71 | Issue: 11 | Pages: No page available

10.1002/pbc.31293 | PMID 39192706 Get It

AbstractA new generation of disease‐specific molecular imaging agents is poised to revolutionize fluorescence‐guided surgery. Pafolacianine has been approved for adult lung and ovarian cancers. We demonstrate a proof of concept for pediatric surgeons treating young adults with pulmonary metastatic sarcomas. Five successful fluorescence‐guided pulmonary metastasectomy operations were performed in young adult patients with metastatic osteosarcoma or Ewing sarcoma following administration of pafolacianine. All osteosarcoma lesions identified using standard techniques were also markedly fluorescent in patients. Novel fluorescent molecular agents targeted to tumor‐specific receptors have promise of increased sensitivity and specificity for detecting metastatic nodules and enhancing surgical clearance of disease.
Surgical management of rare tumors (Part 1)
Stetson, Alyssa , Saluja, Saurabh , Cameron, Danielle B. , Mansfield, Sara A. , Polites, Stephanie F. , Dahl, John P. , Austin, Mary T., Aldrink, Jennifer H. , Christison‐Lagay, Emily , Aldrink, Jennifer H , Christison-Lagay, Emily R , Honeyman, Joshua N.

Mayo Clinic

Pediatric Blood & Cancer | August 26, 2024 | Volume: 72 | Issue: S2 | Pages: No page available

10.1002/pbc.31287 | PMID 39185712 Get It

AbstractWith an annual cumulative occurrence of approximately 15,000 in North America, all childhood cancers are rare. Very rare cancers as defined by both the European Cooperative Study Group for Rare Pediatric Cancers and the Children's Oncology Group fall into two principal categories: those so uncommon (fewer than 2 cases/million) that their study is challenging even through cooperative group efforts (e.g., pleuropulmonary blastoma and desmoplastic small round cell tumor) and those that are far more common in adults and therefore rarely studied in children (e.g., thyroid, melanoma, and gastrointestinal stromal tumor). Treatment strategies for these latter tumors are typically based on adult guidelines, although the pediatric variants of these tumors may harbor different genetic signatures and demonstrate different behavior. If melanoma and differentiated thyroid cancer are excluded, other rare cancer types account for only 2% of the cancers in children aged 0 to 14. This article highlights several of the most common rare tumor types.
Teaching NeuroImage: Hydrocephalus and Ischemic Stroke in an Infant With a Glioneuronal Tumor
Liu, Michael , Vasquez, Alejandra , Keating, Gesina F. , Youssef, Paul E., Liu, Michael , Raghunathan, Aditya , Youssef, Paul, Syc‐Mazurek, Stephanie B. , Raghunathan, Aditya

Mayo Clinic

Neurology | August 23, 2024 | Volume: 103 | Issue: 6 | Pages: No page available

10.1212/wnl.0000000000209791 | PMID 39167751 Get It

A New Era in Menopause Management?
Faubion, Stephanie S. , Shufelt, Chrisandra

Mayo Clinic

JAMA | August 22, 2024 | Volume: 332 | Issue: 16 | Pages: 1335

10.1001/jama.2024.15118 | PMID 39172487 Get It

BRUSH Summer Research Program: Promoting Science Identity in Underrepresented Veterinary and Undergraduate Students
Ewart, Susan , Maves, Benjamin E., Latona, Omolade, Young, Lindsey, Ewart, Susan L , Maves, Benjamin, Sawtelle, Vashti , Watts, Stephanie W. , Yuzbasiyan‐Gurkan, Vilma

Mayo Clinic

Journal of Veterinary Medical Education | August 22, 2024 | Volume: 52 | Issue: 4 | Pages: 560-572

10.3138/jvme-2024-0045 | PMID 39504223 Get It

While all facets of the health care workforce need to diversify, the veterinary profession lags behind in training students from underrepresented populations. The need to increase diversity among health care professionals is not limited to clinicians but extends to those generating new information through biomedical research. To address demographic disparities within the biomedical research community, we provide a summer research program for veterinary and undergraduate students from populations historically underrepresented in the biomedical workforce that is explicitly designed to foster science identity and subsequently increase participants’ interest and success in pursuing biomedical research-related educational and career paths. We hypothesized that participation in this program would enhance science identity, confidence, and pursuit of research-related education and subsequent careers. Three validated survey instruments containing qualitative ordered rating scales were administered to program participants ( N = 57) over the course of the summer in which they participated (2018–2022). Questions asked at two time points were analyzed with a repeated-measures linear mixed-effects model. Significant growth was reported in most topics surveyed over time. Many queries within gains, confidence, and science identity modules displayed significant increases over time or scored high in surveys at both time points. In addition, post-graduate educational and career outcomes were obtained for alumni ( N = 130) of program years 2011–2023; their post-graduate enrollment rates (78%) markedly exceeded national norms. This multidimensional experiential research program, which holistically fosters professional networking and student confidence in research-related endeavors, provides quantifiable growth in research skills and science identity. These gains support students’ persistence in research and biomedical-related educational and career paths.
Artificial intelligence enabled interpretation of ECG images to predict hematopoietic cell transplantation toxicity
Shaffer, Brian C. , Brown, Samantha , Chinapen, Stephanie , Mangold, Kathryn, Lahoud, Oscar , Schaffer, Wendy, Liu, Jennifer E. , Giralt, Sergio , Scordo, Michael , Papadopoulos, Esperanza B. , Landau, Heather , Friedman, Paul A. , Kosmidou, Ioanna , Giralt, Sergio , Papadopoulos, Esperanza , Landau, Heather , Perales, Miguel-Angel , Friedman, Paul A , Attia, Zachi I , Lahoud, Oscar B , López-Jiménez, Francisco , Devlin, Sean M. , Shah, Gunjan L. , Usmani, Saad Z. , Perales, Miguel‐Angel , Gersh, Bernard J. , Attia, Zachi I. , Noseworthy, Peter A.

Mayo Clinic

Blood Advances | August 19, 2024 | Volume: 8 | Issue: 21 | Pages: 5603-5611

10.1182/bloodadvances.2024013636 | PMID 39158065 Get It

Abstract Artificial intelligence (AI)–enabled interpretation of electrocardiogram (ECG) images (AI-ECGs) can identify patterns predictive of future adverse cardiac events. We hypothesized that such an approach would provide prognostic information for the risk of cardiac complications and mortality in patients undergoing hematopoietic cell transplantation (HCT). We retrospectively subjected ECGs obtained before HCT to an externally trained, deep-learning model designed to predict the risk of atrial fibrillation (AF). Included were 1377 patients (849 autologous [auto] HCT and 528 allogeneic [allo] HCT recipients). The median follow-up was 2.9 years. The 3-year cumulative incidence of AF was 9% (95% confidence interval [CI], 7-12) in patients who underwent auto HCT and 13% (10%-16%) in patients who underwent allo HCT. In the entire cohort, pre-HCT AI-ECG estimate of AF risk correlated highly with the development of clinical AF (hazard ratio [HR], 7.37; 95% CI, 3.53-15.4; P < .001), inferior survival (HR, 2.4; 95% CI, 1.3-4.5; P = .004), and greater risk of nonrelapse mortality (NRM; HR, 95% CI, 3.36; 1.39-8.13; P = .007), without increased risk of relapse. Association with mortality was only noted in allo HCT recipients, where the risk of NRM was greater. The use of cyclophosphamide after transplantation resulted in greater 90-day incidence of AF (13% vs 5%; P = .01) compared to calcineurin inhibitor–based graft-versus-host disease prophylaxis, corresponding to temporal changes in AI-ECG AF prediction after HCT. In summary, AI-ECG can inform risk of posttransplant cardiac outcomes and survival in HCT patients and represents a novel strategy for personalized risk assessment.
Synoptic operative reports for pediatric surgical oncology
Baertschiger, Reto M. , Polites, Stephanie F. , Fusco, Joseph , Roach, Jonathan P. , Christison‐Lagay, Emily , Malek, Marcus M. , Gow, Kenneth W. , Baertschiger, Reto M , Polites, Stephanie, Malek, Marcus M , Christison-Lagay, Emily R

Mayo Clinic

Pediatric Blood & Cancer | August 17, 2024 | Volume: 72 | Issue: S2 | Pages: No page available

10.1002/pbc.31280 | PMID 39152638 Get It

AbstractSynoptic operative notes for pediatric surgical oncology provide standardized and structured documentation of surgical procedures performed on pediatric patients with cancer. These reports capture essential details such as preoperative diagnosis, intraoperative findings, surgical technique, and tumor characteristics in a concise and uniform format. By promoting consistency, accuracy, and completeness in reporting, synoptic operative notes facilitate effective communication among multidisciplinary healthcare teams, enhance quality assurance efforts, and streamline data extraction for research purposes. The integration of synoptic reporting within electronic medical record systems further enhances accessibility and usability, ensuring efficient documentation practices and improved patient care outcomes in pediatric surgical oncology.
Clinical presentation and factors associated with gluten exposure in children with celiac disease
Krueger, Andrew , Fahey, Lisa M. , Sun, Qin , Regis, Stephanie , Khavari, Nasim, Jericho, Hilary , Badalyan, Vahe , Absah, Imad , Leonard, Maureen M. , Weisbrod, Vanessa , Hajjat, Temara , Shull, Mary , Silvester, Jocelyn A. , Mallon, Daniel , RAISE‐CD, Silvester, Jocelyn A , Mallon, Daniel , Regis, Stephanie , Weisbrod, Vanessa , Krueger, Andrew, Verma, Ritu , Lee, Dale Young , RAISE‐CD

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | August 16, 2024 | Volume: 79 | Issue: 4 | Pages: 895-904

10.1002/jpn3.12321 | PMID 39149789 Get It

AbstractObjectivesThe prevalence of celiac disease (CeD) is increasing, yet it is still underdiagnosed, in part because of its heterogeneous presentation. Diagnostic criteria are evolving and management with strict adherence to a gluten‐free diet is challenging for many. We aimed to characterize the clinical presentation of CeD among a large multicenter cohort of pediatric patients and to identify factors associated with gluten‐free diet adherence.MethodsPatients with CeD aged 0–18 years were recruited from 11 United States health centers. Parents completed surveys about gluten‐free diet adherence and patient electronic health records were reviewed. Logistic regression analyses were performed to identify risk factors associated with gluten exposure.ResultsCharts were reviewed for 460 children with a median age of 6.4 years. Abdominal pain was reported in 57% of the cohort, but diverse symptoms were identified. Parent surveys were completed for 455 participants. Sixty‐five (14%) participants were at high risk for gluten exposure based on parental reports of weekly or daily gluten exposure or eating gluten by choice in the past year. Participants under the age of 5 years had a lower risk of gluten exposure, while participants without repeat serology testing 18 months after initial diagnosis were at higher risk of gluten exposure.ConclusionsIn a large, multicenter cohort of pediatric CeD patients, clinical presentation is highly variable, necessitating a high index of suspicion to make a diagnosis. Parent surveys indicate that 14% of patients are at high risk of gluten exposure, with patient age and lack of close follow‐up associated with gluten‐free diet adherence.
Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Acharya, Sahaja , Allison, Jenna , Alva, Elizabeth, Arndt, Carola, Benedetti, Daniel J. , Church, Alanna J. , Davidoff, Andrew M. , Desai, Ami V. , DuBois, Steven G. , Fair, Douglas , Farinhas, Joaquim M. , Harrison, Douglas J. , Huang, Frederick S., Iskander, Paul, Kreissman, Susan G. , Macy, Margaret E. , Pashankar, Farzana , Pendyala, Praveen, Polites, Stephanie F. , Rabah, Raja , Shimada, Hiroyuki , Slatnick, Leonora R. , Sokol, Elizabeth , Twist, Clare J. , Vo, Kieuhoa T. , Watt, Tanya , Wolden, Suzanne, Zage, Peter E. , Schonfeld, Ryan, Hang, Lisa, Polites, Stephanie, Bagatell, Rochelle , Park, Julie R. , Aldrink, Jennifer H. , Brown, Erin G. , Cho, Steve K. , Na, Brian , Pinto, Navin

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 16, 2024 | Volume: 22 | Issue: 6 | Pages: 413-433

10.6004/jnccn.2024.0040 | PMID 39151455 Get It

Neuroblastoma is the most common extracranial solid tumor diagnosed in children. This inaugural version of the NCCN Guidelines for Neuroblastoma provides recommendations for the diagnosis, risk classification, and treatment of neuroblastoma. The information in these guidelines was developed by the NCCN Neuroblastoma Panel, a multidisciplinary group of representatives with expertise in neuroblastoma, consisting of pediatric oncologists, radiologists, pathologists, surgeons, and radiation oncologists from NCCN Member Institutions. The evidence-based and consensus recommendations contained in the NCCN Guidelines are intended to guide clinicians in selecting the most appropriate treatments for their patients with this clinically heterogeneous disease.